HC Wainwright Reiterates “Buy” Rating for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ:ALRN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, AnalystRatings.com reports. They presently have a $2.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 69.49% from the stock’s previous close.

ALRN has been the topic of several other reports. William Blair reiterated a “buy” rating on shares of Aileron Therapeutics in a report on Friday, April 24th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aileron Therapeutics in a report on Tuesday, June 2nd. Finally, Zacks Investment Research cut shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $3.50.

Shares of NASDAQ ALRN opened at $1.18 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average price is $1.06 and its two-hundred day moving average price is $0.69. The company has a market cap of $46.20 million, a PE ratio of -1.13 and a beta of 3.71. Aileron Therapeutics has a twelve month low of $0.25 and a twelve month high of $1.99.

Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Monday, May 11th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.04). As a group, research analysts anticipate that Aileron Therapeutics will post -0.67 EPS for the current fiscal year.

In other news, Director Rickenbach Josef H. Von acquired 227,272 shares of the stock in a transaction on Monday, June 8th. The shares were purchased at an average price of $1.10 per share, for a total transaction of $249,999.20. Following the transaction, the director now directly owns 445,460 shares of the company’s stock, valued at $490,006. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALRN. Game Plan Financial Advisors LLC acquired a new position in shares of Aileron Therapeutics during the 4th quarter worth approximately $29,000. Geode Capital Management LLC grew its position in Aileron Therapeutics by 67.1% during the fourth quarter. Geode Capital Management LLC now owns 91,895 shares of the company’s stock worth $52,000 after buying an additional 36,893 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. bought a new position in Aileron Therapeutics during the 4th quarter worth $57,000. Blair William & Co. IL increased its stake in Aileron Therapeutics by 632.7% during the 4th quarter. Blair William & Co. IL now owns 348,044 shares of the company’s stock worth $199,000 after acquiring an additional 300,544 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Aileron Therapeutics by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 491,081 shares of the company’s stock valued at $281,000 after acquiring an additional 150,833 shares in the last quarter. 6.37% of the stock is owned by hedge funds and other institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Further Reading: Understanding the different types of bonds

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.